Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
Pelegrin, M.; Naranjo-Gomez, M.; Piechaczyk, M.
2015-10 / vol 23 / pages 653-665
S0966-842X(15)00154-7 [pii] 10.1016/j.tim.2015.07.005
1878-4380 (Electronic) 0966-842X (Linking)
IGMM team(s) involved in this publication